Eur J Haematol. 2021 Jul 23. doi: 10.1111/ejh.13693. Online ahead of print.
ABSTRACT
OBJECTIVES: Autologous stem cell transplantation is the gold standard for eligible newly diagnosed multiple myeloma patients. Patients are usually hospitalized for administration of mobilization chemotherapy. We aimed to assess safety and efficacy of mobilization therapy with low (2 g/m2 ) and intermediate (3-4 g/m2 ) dose Cyclophosphamide administered as outpatient.
METHODS: A total of 176 consecutive newly diagnosed transplant-eligible myeloma patients receiving outpatient mobilization were retrospectively evaluated. Induction therapy was mainly performed with new drugs (91%).
RESULTS: Chemotherapy was very well tolerated with 16.6% of patients having all-grade adverse events and only 1.2% having severe adverse events. Most frequently reported adverse events were nausea and vomiting grade 1-2 (6.8%). Only 5.7% of patients required hospitalization for adverse events. Stem cell collection was successful in 93.1% of patients, with a median CD34+ harvest of 8.7×106/Kg. Target for 2 ASCT (at least 6 CD34+x106/Kg) was reached by 76.3% of patients. Administration of Plerixafor on demand was necessary in 12.1% of patients.
CONCLUSIONS: Outpatient mobilization with low and intermediate dose Cyclophosphamide appears an efficient and safe procedure, with minimal and manageable adverse events and low rate of hospitalization.
PMID:34297879 | DOI:10.1111/ejh.13693
